利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.012 秒)

    METHOD FOR REPLICATING THE HEPATITIS C VIRUS
    3.
    发明申请
    METHOD FOR REPLICATING THE HEPATITIS C VIRUS 审中-公开
    替代丙型肝炎病毒的方法

    公开(公告)号：US20100159467A1

    公开(公告)日：2010-06-24

    申请号：US12633890

    申请日：2009-12-09

    申请人： CZESLAW WYCHOWSKI ,  GILLES DUVERLIE ,  JEAN DUBUISSON ,  ANDRÉ PILLEZ

    发明人： CZESLAW WYCHOWSKI ,  GILLES DUVERLIE ,  JEAN DUBUISSON ,  ANDRÉ PILLEZ

    IPC分类号： C12Q1/68

    CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N2510/02 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12P21/02 ,  G01N33/5767

    摘要： A process for screening anti-HCV agents, including the steps of introducing a compound to be tested for its anti-HCV properties with transformed Vero/6418 cells, having a nucleic acid selected from the group consisting of a nucleic acid coding for the structural and non-structural proteins of the HCV, a nucleic acid coding for the non-structural proteins of the HCV, and a replicon containing a resistance gene to an antibiotic and a nucleotide sequence coding for the non-structural proteins of the HCV; extracting total RNA of the cells; and analyzing any reduction of the rate, of synthesis of the RNA of the HCV of the cells relative to a control value corresponding to the rates of synthesis of the RNAs of the HCV of the cells in the absence of the tested compound.

    摘要翻译： 一种用于筛选抗HCV药物的方法，包括以下步骤：用转化的Vero / 6418细胞引入待测化合物的抗-HCV特性的化合物，所述方法具有选自编码结构的核酸和 HCV的非结构蛋白，编码HCV的非结构蛋白的核酸和含有抗生素抗性基因的复制子和编码HCV的非结构蛋白的核苷酸序列; 提取细胞的总RNA; 并且相对于在不存在测试化合物的情况下相对于细胞的HCV合成速率的对照值，分析细胞的HCV合成速率的任何降低。

    Techniques for producing site-directed mutagenesis of cloned DNA
    4.
    发明授权
    Techniques for producing site-directed mutagenesis of cloned DNA 失效
    用于产生克隆DNA定点诱变的技术

    公开(公告)号：US5284760A

    公开(公告)日：1994-02-08

    申请号：US764085

    申请日：1991-09-23

    申请人： Stephen M. Feinstone ,  Czeslaw Wychowski ,  Jonathan E. Silver ,  Suzanne U. Emerson

    发明人： Stephen M. Feinstone ,  Czeslaw Wychowski ,  Jonathan E. Silver ,  Suzanne U. Emerson

    IPC分类号： C07K14/10 ,  C07K14/105 ,  C12Q1/68 ,  C12N15/10

    CPC分类号： C12Q1/6858 ,  C07K14/005 ,  C12Q1/6853 ,  C07K2319/00 ,  C12N2770/32434 ,  C12N2770/32622

    摘要： A method is described whereby new cDNA or RNA sequences can be introduced into or substituted for cDNA in any chosen position without specific sequence requirements using the polymerase chain reaction (PCR). The method entails the use of primers which are complementary to the 3' and 5' ends of the desired sequence to be inserted as well as to the 3' and 5' ends of the chosen site of insertion in the acceptor molecule. The desired sequence is amplified by PCR such that single stranded fragments are produced. The single stranded fragment of the desired sequence is then annealed to a single stranded acceptor molecule at the site of insertion and extended to produce a double stranded molecule. The double stranded molecule is then separated into two strands which are identical except that one of the strands contains the desired sequence inserted at the chosen site. A second double stranded molecule is then generated.

    摘要翻译： 描述了一种方法，其中可以使用聚合酶链式反应（PCR）将新的cDNA或RNA序列引入任何选定位置或用任何特定序列要求代替cDNA。 该方法需要使用与待插入的所需序列的3'和5'末端互补的引物以及在受体分子中所选插入位点的3'和5'末端。 通过PCR扩增所需的序列，从而产生单链片段。 然后将所需序列的单链片段在插入位点退火至单链受体分子并延伸以产生双链分子。 然后将双链分子分成两条相同的链，除了一条链含有插入所选位点的所需序列外。 然后产生第二双链分子。

    Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus
    5.
    发明申请
    Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus 审中-公开
    使用表没食子儿茶素Gallate作为抗丙型肝炎病毒感染的抗病毒剂

    公开(公告)号：US20140088184A1

    公开(公告)日：2014-03-27

    申请号：US14008031

    申请日：2012-03-28

    申请人： Karin Seron ,  Jean Dubuisson ,  Yves Rouille ,  Czeslaw Wychowski

    发明人： Karin Seron ,  Jean Dubuisson ,  Yves Rouille ,  Czeslaw Wychowski

    IPC分类号： A61K31/353 ,  A61K45/06

    CPC分类号： A61K31/353 ,  A61K31/352 ,  A61K45/06 ,  C12N2770/24211

    摘要： The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I).

    摘要翻译： 本发明涉及具有式I的类黄酮化合物，其中R 3，R 5和/或R 7是具有式II的基团，或R 1和R 2都是OH基团，或其药学上可接受的盐或酯之一， 用作抗病毒剂用于治疗和/或预防丙型肝炎病毒（HCV）感染。 本发明还涉及用于降低HCV的感染性或使HCV失活的离体方法，包括使所述丙型肝炎病毒与具有式（I）的化合物接触的步骤。